Antonio Teixeira
Neurology · San Antonio, TXNPI 1639544851
Payments from drug & device makers
Across 33 payments — averaging $1481.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38K
- Neurocrine Biosciences, Inc.$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Lundbeck LLC$1K
- Teva Pharmaceuticals USA, Inc.$206
- AbbVie$55
- plus $17 from 1 others
What the payments were for
- Consulting fees$4,50065%
- Speaking & faculty fees$1,17017%
- Travel & lodging$4627%
- Food & beverage$75811%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $38,314 |
| Neurocrine Biosciences, Inc. | 13 | $5,459 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,675 |
| Lundbeck LLC | 1 | $1,170 |
| Teva Pharmaceuticals USA, Inc. | 2 | $206 |
| AbbVie | 1 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,895 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 35 | $608 |
| Mirtazapine | 22 | $368 |
| Trazodone Hcl | 27 | $281 |
| Divalproex Sodium | 14 | $271 |
| Donepezil Hcl | 23 | $169 |
| Escitalopram Oxalate | 17 | $137 |
| Clonazepam | 18 | $111 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $83 |
| Sertraline Hcl | 24 | $81 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Antonio
- Ann BassSan Antonio$12.3M
- Juan Ramirez CastanedaSan Antonio$1.1M
- Eleni VaouSan Antonio$584K
- Rebecca RomeroSan Antonio$569K
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.